Drug Profile


Alternative Names: KRN 568; Norcalin; NPS R 568; R 568

Latest Information Update: 22 Nov 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NPS Pharmaceuticals
  • Developer Kirin Brewery; NPS Pharmaceuticals
  • Class Antirheumatics; Osteoporosis therapies; Small molecules
  • Mechanism of Action Calcium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperparathyroidism; Osteitis; Postmenopausal osteoporosis; Rheumatic disorders

Most Recent Events

  • 22 Nov 2000 Discontinued-II for Hyperparathyroidism in Japan (PO)
  • 22 Nov 2000 Discontinued-II for Hyperparathyroidism in USA (PO)
  • 22 Nov 2000 Discontinued-II for Postmenopausal osteoporosis (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top